Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer
But Has Ground To Make Up On Tecentriq
Executive Summary
An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
You may also be interested in...
Keytruda TNBC Approval Now More Likely, But Data Is Bad News For pCR Surrogate Endpoint
Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.
Keytruda To Enjoy First-To-Market Advantage As TNBC Approval Now More Likely
Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.
Merck & Co.’s Keytruda Gets Fighting Chance In TNBC
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.